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Background. It is difﬁcult to determine whether early tuberculosis treatment is effective in reducing the infec-
tiousness of patients’ sputum, because culture takes weeks and conventional acid-fast sputum microscopy and mo-
lecular tests cannot differentiate live from dead tuberculosis.
Methods. To assess treatment response, sputum samples (n = 124) from unselected patients (n = 35) with spu-
tum microscopy–positive tuberculosis were tested pretreatment and after 3, 6, and 9 days of empiric ﬁrst-line ther-
apy. Tuberculosis quantitative viability microscopy with ﬂuorescein diacetate, quantitative culture, and acid-fast
auramine microscopy were all performed in triplicate.
Results. Tuberculosis quantitative viability microscopy predicted quantitative culture results such that 76% of
results agreed within ±1 logarithm (rS = 0.85; P < .0001). In 31 patients with non-multidrug-resistant (MDR) tuber-
culosis, viability and quantitative culture results approximately halved (both 0.27 log reduction, P < .001) daily. For
patients with non-MDR tuberculosis and available data, by treatment day 9 there was a >10-fold reduction in via-
bility in 100% (24/24) of cases and quantitative culture in 95% (19/20) of cases. Four other patients subsequently
found to have MDR tuberculosis had no signiﬁcant changes in viability (P = .4) or quantitative culture (P = .6) results
during early treatment. The change in viability and quantitative culture results during early treatment differed sig-
niﬁcantly between patients with non-MDR tuberculosis and those with MDR tuberculosis (both P < .001). Acid-fast
microscopy results changed little during early treatment, and this change was similar for non-MDR tuberculosis vs
MDR tuberculosis (P = .6).
Conclusions. Tuberculosis quantitative viability microscopy is a simple test that within 1 hour predicted quan-
titative culture results that became available weeks later, rapidly indicating whether patients were responding to
tuberculosis therapy.
Keywords. ﬂuorescein diacetate; viability stain; vital stain tuberculosis; early bactericidal activity; multidrug-
resistant tuberculosis.
Concentrations of viable Mycobacterium tuberculosis in
patients’ sputum are demonstrated by quantitative cul-
ture to decline rapidly during the ﬁrst days of adequate
tuberculosis treatment [1]. Quantifying this early
treatment response identiﬁes patients whose treatment
is inadequate [1–3], potentially allowing drug suscept-
ibility testing (DST) to be provided sooner to patients
most likely to beneﬁt. This is important because, al-
though universal DST is a priority, resources are so
limited that globally only 5% of tuberculosis patients
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are tested [4]. Assessing early treatment response may help de-
tect not only drug resistance, but also other causes of incipient
treatment failure including malabsorption and poor adher-
ence, which are difﬁcult to detect.
There is no appropriate-technology test for quantifying via-
bleM. tuberculosis in sputum. Quantitative culture is technically
demanding, infrequently available, and provides results that are
weeks out of date [5]. The GeneXpert MTB/RIF assay [6] and
acid-fast microscopy using the Ziehl-Neelsen or auramine
stains do not differentiate viable from nonviableM. tuberculosis,
so they cannot assess early treatment response [7]. Molecular
tests quantifying ribonucleic acid in viable M. tuberculosis are
not feasible in resource-constrained settings [8]. Consequently
the detection of failing tuberculosis treatment is often delayed,
risking morbidity, mortality, and contagion [9].
Fluorescein diacetate is a viability stain that ﬂuoresces only
after hydrolysis by nonspeciﬁc esterases in the cytoplasm of vi-
able, metabolically active bacteria [10]. Fluorescein diacetate mi-
croscopy assesses the viability of microorganisms, including the
mycobacteria that cause leprosy and tuberculosis [10, 11]. Fluo-
rescein diacetate has recently been used with tuberculosis spu-
tum microscopy to predict culture positivity [12, 13] and with
ﬂow cytometry to determine drug susceptibility [14–16].
We hypothesized that sputum tuberculosis quantitative viability
microscopy (henceforth termed “viability”) would predict the con-
centration of culturableM. tuberculosis, indicating whether patients
are responding to tuberculosis treatment, potentially informing
clinical care and infection control decisions. To test these hypothe-
ses, we optimized viability microscopy and compared results with
culture and acid-fast microscopy during early treatment. We have
presented early ﬁndings [17–19] and here report ﬁnal results.
MATERIALS AND METHODS
Ethics
All participants gave informed written consent. The interna-
tionally accredited ethics committee of the Universidad Peruana
Cayetano Heredia approved the study. All clinically relevant re-
sults were provided to participants and their physicians in col-
laboration with the Ministry of Health. This research had no
role in patient care, which was free for all patients with suspect-
ed tuberculosis and was not delayed or modiﬁed by participa-
tion. Patients received empiric ﬁrst-line tuberculosis therapy
with clinic-based direct observation of every dose from the tu-
berculosis program, according to Peruvian policy, as detailed in
Supplementary Table 1 [20, 21].
Inclusion Criteria
Inclusion criteria were unselected adults diagnosed with spu-
tum smear microscopy–positive tuberculosis disease in shanty-
towns in Ventanilla, Peru [22]. Patients also had to be available
to collect the ﬁrst baseline sputum sample prior to commencing
treatment, and all sputa were collected over 12 hours to reduce
random variation between samples.
Specimens
Single sputum samples were collected pretreatment (day 0), and
on treatment days 3, 6, and 9. DST results became available and
could inﬂuence treatment only after these samples were collected.
Patients
Patients were interviewed at recruitment from 2006 to 2007
(Table 1). Radiography was not a routine part of tuberculosis
management and was not studied [20].We made follow-up visits
every 3 years until 2013 to ask whether tuberculosis had recurred,
screen ex-patients for respiratory symptoms, and offer sympto-
matic ex-patients tuberculosis testing with sputum culture. We
categorized treatment outcome as “good” (cured or completed
treatment without treatment failure as assessed by the tuberculosis
program, and with no recurrence) or “adverse” (treatment failure,
noncompletion, death during treatment, or recurrence) [23, 24].
Processing
Sputum was collected in patients’ homes at room temperature,
transported at 4°C, and decontaminated within 24 hours by
mixing 2 mL of sputum with 2 mL 4% sodium hydroxide,
2.9% sodium citrate, 0.5% N-acetyl-L-cysteine [25]. Reagents
were obtained from Sigma. After 20 minutes, excess phos-
phate-buffered saline (PBS; pH 6.8) was added and centrifuged
(15 minutes at 3000g); the pellet was resuspended in 2 mL PBS,
immediately smeared onto microscope slides with 10 µL bovine
serum albumin for adhesion, and dried at room temperature.
Samples then underwent viability microscopy, quantitative cul-
ture, and acid-fast microscopy, each in triplicate. This standard-
ized decontamination protocol was used, and the exact smear
area was marked on slides with a hydrophobic pen to reduce
processing variability between the triplicate smears.
Viability
One hundred microliters of decontaminated sputum was
smeared over 1 cm2 area of the microscope slide (20 times great-
er density than for acid-fast microscopy). Fluorescein diacetate
staining [13] used a stock 5 mg in 1 mL diluent (40% acetone in
PBS) solution, which was diluted daily to 20 µg/mL in diluent
and soaked onto a 1 cm2 piece of Whatman grade 3 ﬁlter paper
that was incubated on the smear at 37°C for 20 minutes. The
paper was discarded, the slide allowed to dry in the dark for
10 minutes, and microscopy performed immediately. Concur-
rent nonviable counterstaining was not used.
Acid-Fast Staining
Ten microliters of decontaminated sputum was smeared over
2 cm2 area of the microscope slide, dried, heat-ﬁxed by passing
Tuberculosis Viability Staining During Treatment • CID 2015:60 (15 April) • 1187
through a ﬂame, and auramine stained by ﬂooding with 0.1%
auramine (15 minutes) and 0.5% acid-alcohol decolorizing sol-
ution (2 minutes); rinsing with distilled water; ﬂooding with
0.5% potassium permanganate (2 minutes); rinsing with dis-
tilled water; drying; storing in the dark; and performing micros-
copy within 6 hours [25].
Microscopy
Visible bacteria were counted in 100 consecutive microscopy
ﬁelds at ×1000 magniﬁcation (approximately 2 mm2 [26]).
Concentrations of stained bacteria per milliliter sample were
calculated and are termed “viability” and “acid-fast microscopy.”
Cultures
Cultures used the microscopic-observation drug susceptibility
(MODS) technique [27, 28] adapted to be quantitative [5]. A
1:10 dilution of 50 µL decontaminated sputum in 450 µL
culture broth [28] was mixed by pipetting; 50 µL was mixed
into a 1:100 dilution well, and then into a 1:1000 dilution
well. Cultures were sealed in unsupplemented room air, incu-
bated at 37°C, and examined with an inverted microscope for
cording colonies to determine positivity. This is labor intensive
and was performed 3 times weekly [5], making time to culture
positivity data poorly discriminatory. Consequently, the prima-
ry quantiﬁcation of M. tuberculosis growth was colony-forming
units as described elsewhere [5], divided by the sample volume
(mL) inoculated into that culture, and termed “quantitative cul-
ture.” Positive cultures were conﬁrmed to be M. tuberculosis
with the Capilia assay (Tauns, Tokyo, Japan).
Drug Susceptibility Testing
Isoniazid and rifampicin susceptibility of pretreatment samples
were analyzed with the standard nonquantitative MODS tech-
nique [27, 28] and the tetrazolium microplate assay (TEMA) [29].
Table 1. Baseline Patient and Laboratory Data
Characteristic Day 0 Day 3 Day 6 Day 9
Laboratory results
Samples collected, No. 35 34 30 25
Viability microscopy positive, % (no./No.) 94% (33/35) 76% (26/34) 53% (16/30) 24% (6/25)
Culture positive, % (no./No.) 100% (33/33)a,b 94% (29/31)a 81% (21/26)a 64% (14/22)a
Acid-fast microscopy positive, % (no./No.) 100% (35/35) 97% (33/34) 97% (29/30) 88% (22/25)
Multidrug resistant, % (no./No.) 12% (4/35)
Isoniazid monoresistant, % (no./No.) 5.60% (2/35)
Rifampicin monoresistant, % (no./No.) 0.0% (0/35)
Ethambutol resistant, % (no./No.)c 37% (13/35)
Streptomycin resistant, % (no./No.)c 34% (12/35)
Ciprofloxacin resistant, % (no./No.)c 0.0% (0/35)
Capreomycin resistant, % (no./No.)c 2.9% (1/35)
Patient characteristics
Age, median, y (IQR) 26 (22–35)
Sex, % male (no./No.) 57% (20/35)
Body mass index, mean (SD) 21 (2.7)
Poverty indicator: median food spending, US$/week (IQR) 6.3 (4.0–8.7)
BCG, % with scar (no./No.) 94% (30/35)
Past tuberculosis diagnosis, % (no./No.) 6.30% (2/35)
HIV, % (no./No.) 0.0% (0/35)
Characteristics of illness
Productive cough, % (no./No.) 94% (30/35)
Fever, % (no./No.) 69% (22/35)
Night sweats, % (no./No.) 72% (23/35)
Days with symptoms, median (IQR) 30 (20–60)
Patient and laboratory data are shown at the time of recruitment (day 0) and on days 3, 6, and 9 of treatment. Denominators vary because of 11% missing samples
and 10% contaminated quantitative cultures.
Abbreviations: BCG, bacillus Calmette-Guerin; HIV, human immunodeficiency virus; IQR, interquartile range; no., number of participants with that characteristic; No.,
number of participants with available data; SD, standard deviation.
a Twelve quantitative culture results were unavailable because of contamination of the cultures.
b All pretreatment (day 0) samples were culture-positive in conventional nonquantitative microscopic-observation drug susceptibility (see “Results” section).
c Drug susceptibility results from tetrazolium microplate assay only.
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Analysis
Recruitment took place over 12 months, so recruitment and fol-
low-up samples from different patients were analyzed concur-
rently. Staff were blinded to all other clinical and laboratory
data. Because artifacts can cause weakly false-positive microsco-
py results, and in accordance with Peruvian policy for acid-fast
microscopy, all microscopy was considered positive if ≥10 ob-
jects with the appearance of M. tuberculosis were seen [21]. The
international MODS protocol determined that ≥2 colonies in-
dicated a positive result because single colonies may result from
cross-contamination [30]. Bacterial counts were exponentially
distributed, so were transformed to their base-10 logarithm
(after zero values were transformed to the midpoint between
zero and the detection threshold) and are reported as geometric
means with 95% conﬁdence intervals (CIs). Parametric
data were summarized as mean with standard deviation (SD).
Nonparametric data were summarized as median and inter-
quartile range. Linear regression used random effects to adjust
for between-patient variations. The study sample size was re-
source limited, and treatment response power calculations
were not done. All analyses were 2-tailed and performed with
Stata software version 11. All data are reported to 2 signiﬁcant
ﬁgures.
RESULTS
Pretreatment Sputum
Pretreatment sputum was available from 35 patients whose
characteristics are shown in Table 1. Our research protocol re-
quirement for patients to collect sputum for 12 hours before
commencing treatment slowed recruitment because tuber-
culosis treatment was usually started immediately following di-
agnosis. This logistical limitation was unrelated to patient
characteristics, so participants were locally representative. All
participants had positive culture and acid-fast microscopy re-
sults and had viability-positive bacteria visualized; 94% (33/
35) had viability above the threshold for positivity.
Sputum Samples
All sputa underwent microscopy. Sputa were available for 89%
(124/140) of the intended samples on days 0, 3, 6, and 9. Quan-
titative cultures provided interpretable results for 90% (112/
124) of samples (Table 1). Viability predicted quantitative cul-
ture (Figure 1A), such that 76% of results agreed within ±1 log-
arithm and 96% within ±2 logarithms, and there was good
correlation (rS = 0.85; P < .001). Similarly, 78% of the changes
in viability during each interval of 3 days’ treatment (baseline
Figure 1. Tuberculosis quantitative viability microscopy prediction of quantitative culture results. Histograms show for each sputum sample the
difference between quantitative tuberculosis viability microscopy results minus quantitative culture results (A) and the change in quantitative tubercu-
losis viability microscopy results minus the change in quantitative culture results (B ) during each interval of 3 days of treatment (baseline 0 to 3 days, 3
to 6 days, and 6 to 9 days of follow-up). All results are shown on a log scale (“log” indicates base-10 logarithm); 76%–78% of results agreed within ±1
logarithm and 96%–97% agreed within ±2 logarithms. Microscopy results are geometric means of triplicate identical slides from each sample (see also
Supplementary Figure 1).
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0 to 3 days, 3 to 6 days, and 6 to 9 days of follow-up) predicted
within ±1 logarithm of the changes in quantitative culture
(Figure 1B). Viability correlated with time to culture positivity
(rS =−0.50; P < .0001), and time to culture positivity correlated
with quantitative culture (rS = −0.58; P < .0001).
Drug Susceptibility Testing
DST results were 100% concordant between MODS and TEMA.
Non-Multidrug-Resistant Tuberculosis
Eighty-nine percent (31/35) of patients had non-multidrug-
resistant (MDR) tuberculosis, including 2 patients with isoniazid
monoresistance (Figure 2). Compared with pretreatment, mean
viability for patients with non-MDR tuberculosis after 3, 6, and
9 days of treatment reduced 11-fold, 43-fold, and 250-fold,
respectively (all P < .001). By treatment day 9, viability reduced
>10-fold in all patients with non-MDR tuberculosis and became
negative for 79% (19/24). Quantitative culture mean results for
patients with non-MDR tuberculosis after 3, 6, and 9 days of
treatment reduced 15-fold, 46-fold, and 190-fold, respectively,
compared with pretreatment (all P < .001). By treatment day
9, quantitative culture had reduced >10-fold in 95% (19/20)
of patients with non-MDR tuberculosis and became negative
for 38% (8/21). Acid-fast microscopy mean results fell <5-fold
throughout early treatment, so by treatment day 9, acid-fast mi-
croscopy had reduced >10-fold in only 25% (6/24) of patients
with non-MDR tuberculosis and became negative in only 13%
(3/24). Regression analysis (Table 2) demonstrated that in pa-
tients with non-MDR tuberculosis, viability approximately
halved daily (0.27 log; P < .001), as did quantitative culture
Figure 2. Treatment response for 31 patients with non-multidrug-resistant tuberculosis (TB) on days 0, 3, 6, and 9 of tuberculosis treatment for each
patient (A), mean of all patients (B ), and percentage of patients with <10-fold reduction (C). The x-axis shows days of treatment. Dashed lines indicate
cutoffs for positivity. Proportion viability was calculated by dividing concentrations of viability-positive bacteria by concentrations of acid-fast microscopy–
positive bacteria. Similarly, proportion culturability was calculated by dividing quantitative culture results by concentrations of acid-fast microscopy–positive
bacteria. Microscopy results are geometric means of triplicate identical slides from each sample (see also Supplementary Figure 2).
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(0.27 log; P < .001). Acid-fast microscopy changed little, reduc-
ing by only 0.07 log daily (P = .04).
MDR Tuberculosis
In the 11% (4/35) of patients with MDR tuberculosis, there were
no signiﬁcant changes in viability (P = .4) or quantitative cul-
ture (P = .6) during treatment (Table 2), but only 12 samples
were available (Figure 3).
Non-MDR Tuberculosis Versus MDR Tuberculosis
Changes in viability and quantitative culture during treatment
differed signiﬁcantly for patients with non-MDR tuberculosis
vs MDR tuberculosis (both P < .001; Table 2). Viability changes
were signiﬁcantly greater for non-MDR tuberculosis than MDR
tuberculosis after 3, 6, and 9 days of treatment (all P < .001).
Quantitative culture changes were signiﬁcantly greater for
non-MDR tuberculosis vs MDR tuberculosis after 6 and 9
days treatment (P = .001 and P = .04, respectively). Acid-fast
microscopy was similar comparing patients with non-MDR tu-
berculosis vs MDR tuberculosis overall and after 3, 6, and 9 days
treatment (P = .6, P = .2, P = .08, and P = .3, respectively).
Proportion Viability and Culturability
For every decontaminated sputum, per-milliliter concentrations
were greater for acid-fast microscopy than for viability and
quantitative culture (both P < .001). Proportion viability was
calculated by dividing concentrations of viability-positive
bacteria by concentrations of acid-fast microscopy–positive
bacteria. Similarly, proportion culturability was calculated by
dividing the quantitative culture results by concentrations of
acid-fast microscopy–positive bacteria. For patients with non-
MDR tuberculosis (Figure 2), proportion viability and proportion
culturability fell during treatment (both P < .001). Consequent-
ly, for patients with non-MDR tuberculosis by treatment day 9,
there had been a >10-fold fall in proportion viability for
96% (23/24) of patients and proportion culturability for 80%
(16/20) of patients. In contrast, for the few patients with MDR
tuberculosis (Figure 3), there was no signiﬁcant change in pro-
portion viability or proportion culturability during treatment
(both P > .4).
Microscopy Reproducibility
Linear regression demonstrated that variation between triplicate
slides accounted for no more than 5% of the variation between
microscopy results (ρ = 0.95). Consequently, 100% of ﬁrst slides
predicted geometric mean results of triplicate (ie, ﬁrst, second,
and third) slides within ±1 logarithm for viability (Figure 4A)
and 99% for acid-fast microscopy (Figure 4B). The results of
all the above-mentioned analyses were little changed by using
only ﬁrst slide results (see Supplementary Data).
Clinical Outcomes
All patients had outcome assessed at the time of treatment com-
pletion. All 31 patients with non-MDR tuberculosis were cured;
Table 2. Regression Analysis of Laboratory Results During Early Treatment
Variables
Viability Microscopy Quantitative Culture Acid-Fast Microscopy
Coefficient
(Difference
in Log
Concentration) 95% CI
P
Value
Coefficient
(Difference
in Log
Concentration) 95% CI
P
Value
Coefficient
(Difference
in Log
Concentration) 95% CI
P
Value
Day 0
(pretreatment):
difference in
concentration for
MDR tuberculosis
vs non-MDR
tuberculosis
−0.48 −1.2 to .27 .2 −0.39 −1.3 to .55 .4 −0.073 −.62 to .48 .8
Non-MDR
tuberculosis: daily
change in
concentration
during treatment
−0.27 −.29 to −.25 <.001 −0.27 −.29 to −.25 <.001 −0.070 −.085 to −.056 <.001
MDR tuberculosis:
daily change in
concentration
during treatment
−0.028 −.10 to .044 .4 −0.019 −.095 to .057 .6 −0.056 −.11 to .0033 .04
This table demonstrates the effects of MDR tuberculosis and days of treatment on laboratory results. There was very strong evidence for an interaction between
MDR tuberculosis and daily change in concentration for both viability microscopy and quantitative culture (both P < .001), but no evidence of an interaction for acid-
fast microscopy (P = .6). Microscopy results are geometric means of triplicate identical slides from each sample (see also Supplementary Table 2). The values in bold
are statistically significant.
Abbreviations: CI, confidence interval; log, base-10 logarithm; MDR, multidrug resistant.
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all but 1 were followed up for ≥3 years, and no recurrences were
identiﬁed. All 4 patients with MDR tuberculosis had adverse
outcomes: 1 patient had treatment suspended and the 3 other
patients died. These deaths occurred 22 days, 10 months, and
11 months after initially commencing therapy.
DISCUSSION
Tuberculosis quantitative viability microscopy with ﬂuorescein
diacetate staining for metabolically active bacteria accurately
predicted the concentration of culturableM. tuberculosis in spu-
tum. Viability microscopy took <1 hour and was less resource-
intensive, requiring only basic skills that were already available,
whereas quantitative culture took weeks and required more lab-
oratory equipment and expertise. Over the ﬁrst 9 days of tuber-
culosis treatment, viability microscopy reliably predicted
changes in culturable M. tuberculosis concentrations.
Viability and quantitative culture changes appeared to sepa-
rate into 2 distinct patterns during early treatment depending
on whether patients had MDR tuberculosis. For patients with
non-MDR tuberculosis, after 3 days, treatment mean viability
and quantitative culture results fell by >90% and by day 9 by
99.6%. This concurs with early bactericidal activity and serial
sputum colony count studies of tuberculosis treatment re-
sponse, which reported exponential isoniazid-mediated decline
in culturable M. tuberculosis during the ﬁrst days of treatment,
followed by slower rifampicin-mediated killing [1, 3, 31, 32].
Acid-fast microscopy changed little during early treatment, so
results diverged from viability and quantitative culture as treat-
ment continued [2]. In contrast to these results for patients with
non-MDR tuberculosis, viability and quantitative culture for the
few patients with MDR tuberculosis differed signiﬁcantly be-
cause they did not decrease during early treatment.
Studies in Bangladesh and Thailand reported that “positive-
vs-negative” viability microscopy after 2 months treatment
identiﬁed patients needing DST for probable MDR tuberculosis
[33–35]. Here we demonstrate the value of a modiﬁed quantita-
tive viability microscopy technique to screen patients with tu-
berculosis for poor treatment response and MDR tuberculosis
within 9 days of starting treatment. Patients with MDR tuber-
culosis have worse outcomes, and viability microscopy during
early treatment may allow the sparse capacity for DST to be
Figure 3. Treatment response for 4 patients with multidrug-resistant tuberculosis (TB) on days 0, 3, 6, and 9 of tuberculosis treatment for each patient (A)
and mean of all patients (B ). The x-axis shows days of treatment. Dashed lines indicate cutoffs for positivity. Proportion viability was calculated by dividing
concentrations of viability-positive bacteria by concentrations of acid-fast microscopy–positive bacteria. Similarly, proportion culturability was calculated by
dividing concentrations of culture-positive bacteria by concentrations of acid-fast microscopy–positive bacteria. Microscopy results are geometric means of
triplicate identical slides from each sample (see also Supplementary Figure 3).
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provided to the patients most likely to have MDR tuberculosis
[4]. This has the potential to improve patient outcomes and re-
duce MDR tuberculosis dissemination [36]. Future research
should also assess whether viability microscopy during early
treatment identiﬁes treatment that is failing because of factors
such as malabsorption or inadequate adherence, which are dif-
ﬁcult to detect.
We analyzed viability microscopy not only as viableM. tuber-
culosis concentrations, but also as proportion viability that was
calculated as the viability divided by acid-fast microscopy re-
sults. We included this approach in case low-quality sputum
specimens (or saliva submitted instead of sputum) caused mis-
leading results, but this did not occur in our study, which used
sputum samples collected at home over 12-hour periods. Our
results suggest that the simpler assessment of the concentration
of viable M. tuberculosis was as reliable, more consistent be-
tween samples, and easier to analyze than proportion viability.
To reduce the potential effect of random variation between mi-
croscopy slides, we empirically performed all microscopy tests
on identical triplicate slides from each specimen. However, this
increased workload, and we found that results from only the
ﬁrst microscopy slide gave similar results, perhaps because spu-
tum homogenization and processing were carefully standard-
ized to reduce slide-to-slide variations and the risk of bias
comparing results between different techniques. We therefore
recommend that in the future only a single slide is prepared
for each microscopy technique from each sample.
The skills required and reagent costs for viability microscopy
were similar to those in routine use in many settings for acid-
fast microscopy. A ﬂuorescent microscope is required but their
availability is increasing and costs falling because of LED (light-
emitting diode) technology and because the World Health
Organization has recommended they be used to increase the
sensitivity of acid-fast microscopy for routine tuberculosis
diagnostic testing [37]. Although we used a 37°C incubator to
reduce potential day-to-day variations in this research, inexpen-
sive portable incubators may be fabricated or purchased, and we
are evaluating whether incubation may be omitted. Thus, viabil-
ity microscopy may be considered an appropriate-technology
test for use in basic laboratories in resource-constrained settings.
Study limitations include that microscopy was only used in
patients with initially acid-fast microscopy–positive tuberculo-
sis, which corresponded with >100 000M. tuberculosis/mL spu-
tum (Figures 2 and 3), as in previous research [26]. However,
ﬁlters or centrifugation concentrate M. tuberculosis from spu-
tum and may reduce this limitation [38]. Other limitations in-
cluded the study size because of numbers of patients recruited,
missing samples when patients could not be located, the lack of
pyrazinamide susceptibility testing, and some uninterpretable
contaminated cultures. The culture contamination rate was
within the range of previous studies using MODS but was high-
er than average [39], perhaps because samples were collected
over a longer-than-typical interval (12 hours). The small num-
ber of patients with MDR tuberculosis and their few samples are
important limitations to be addressed in future research. De-
spite these limitations, the study size was sufﬁcient to demon-
strate statistically signiﬁcant viability differences between
patients with non-MDR tuberculosis vs MDR tuberculosis. To
extend these ﬁndings, we are commencing a larger multisite
study assessing the potential programmatic value of these
Figure 4. Comparison of results for ﬁrst microscopy slides vs geometric means. Histograms showing for each sputum sample the difference between
quantitative tuberculosis viability microscopy results (A) and the acid-fast microscopy results for ﬁrst microscopy slides vs geometric means of the results (B)
for the ﬁrst, second and third slides. All results are shown on a log scale (“log” indicates base-10 logarithm); 100% of results agreed within ±1 logarithm.
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ﬁndings by including more patients with MDR tuberculosis and
human immunodeﬁciency virus coinfection and assessing their
single “spot” (not 12-hour) sputum tested with single-slide vi-
ability microscopy prior to and 14 days after commencing
treatment.
Here we show that viability microscopy rapidly demonstrated
when treatment killed M. tuberculosis in patients’ sputum, ren-
dering that sputum culture negative and presumably noninfec-
tious. It is frequently difﬁcult to assess when the infectiousness
of patients is being reduced by treatment. Consequently, infec-
tion control precautions may either be prolonged until sputum
acid-fast or culture results become negative, or stopped based
on unreliable indicators such as symptomatic response or an ar-
bitrary number of days of treatment [40]. Assessing patient in-
fectiousness is challenging [36], and in separate research we are
assessing whether the wide, naturally occurring variations inM.
tuberculosis proportion viability in pretreatment sputum had
implications for patients’ infectiousness to their contacts. How-
ever, tuberculosis culture is the gold-standard test for the infec-
tiousness of sputum, and infection control assessments are
often based upon sputum culture results. Thus, by rapidly pre-
dicting quantitative culture results, viability microscopy may
provide timely evidence on which to base infection control
decisions.
Tuberculosis quantitative viability microscopy predicted in 1
hour the results of sputum culture that became available weeks
later. In the resource-constrained settings where most tubercu-
losis occurs, this appropriate-technology technique had prom-
ising results for informing decisions concerning DST and
changes in treatment and infection control measures.
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